Venture Capital
i&i Biotech Fund
i&i Biotech Fund backs early-stage and high-growth companies, typically pre-profit, from Luxembourg. It states a focus on healthcare & life sciences.
Portfolio
Disclosed holdings
Companies i&i Biotech Fund lists on its own website. 10 carry a stated investment year.
| Company | Invested | Years held | Recorded transaction |
|---|---|---|---|
| Dracen Pharmaceuticals | 2021 | 5 | — |
| CasInvent | 2022 | 4 | — |
| Celeris Therapeutics | 2022 | 4 | — |
| Enzyre | 2022 | 4 | — |
| Nanoligent | 2022 | 4 | — |
| Sampling Human | 2022 | 4 | — |
| Sophomer | 2022 | 4 | — |
| Captain T Cell | 2023 | 3 | — |
| Delta Life Science | 2023 | 3 | — |
| HeartBeat.bio | 2023 | 3 | — |
| Antiverse | — | — | — |
| EIF | — | — | — |
| IOCB Tech | — | — | — |
| LAM-X | — | — | — |
| Ternary Therapeutics | — | — | — |
| Theorema | — | — | — |
| Vasa Therapeutics | — | — | — |
| cuip.cz | — | — | — |
| iQure | — | — | — |
| iniprague.com | — | — | — |
| uochb.cz | — | — | — |
Compiled from i&i Biotech Fund’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.
Valuation context
Transaction values in Healthcare & Life Sciences
What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.
The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.
For owners
Own a healthcare & life sciences business?
The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.
Request a confidential valuationFor investors
Is this i&i Biotech Fund?
Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.
Claim or correct this profileTargeted buyer search
Which hundred of these would actually buy your business?
A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.
Comparable investors
Similar mandates
Other venture capital investors active in healthcare & life sciences.